Advisory Committee Recommends Avastin, Herceptin Biosimilars

0
61

An FDA advisory panel unanimously recommended that the agency approve two biosimilars for the cancer treatments Avastin (bevacizumab) and Herceptin (trastuzumab).

Comments

comments